The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation• Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?• Breathing Engineered Bacteria: A New Approach to Treating Lung Disease• Vedanta Biosciences Secures $60 Million in Funding Ahead of Pivotal Phase 3 Data• Gut fungi may hold the key to treating Asthma worldwide•

Category: Infectious Disease & AMR

Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101
Clinical & Manufacturing

Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101

JAN 24, 2023
World’s First Computational Reconstruction of a Virus in its Biological Entirety
Basic & Discovery Research

World’s First Computational Reconstruction of a Virus in its Biological Entirety

JAN 23, 2023
IBT secures platform for pharma grade probiotic to prevent antibiotic resistant hospital acquired infections
Infectious Disease & AMR

IBT secures platform for pharma grade probiotic to prevent antibiotic resistant hospital acquired infections

JAN 16, 2023
Atomic structure of a staphylococcal bacteriophage using cryo-electron microscopy
Basic & Discovery Research

Atomic structure of a staphylococcal bacteriophage using cryo-electron microscopy

DEC 21, 2022
FDA Approves First Fecal Microbiota Product
Editor's Choice

FDA Approves First Fecal Microbiota Product

DEC 1, 2022
Anti-anaerobic antibiotics associated with increased risk of mortality in critically ill patients
Basic & Discovery Research

Anti-anaerobic antibiotics associated with increased risk of mortality in critically ill patients

OCT 19, 2022
Pherecydes Pharma Announces Registration of Its in Vitro Diagnostic Test in Accordance With EC Directives
Infectious Disease & AMR

Pherecydes Pharma Announces Registration of Its in Vitro Diagnostic Test in Accordance With EC Directives

SEP 13, 2022
New needle-free nasal vaccine shows promise for COVID-19
Infectious Disease & AMR

New needle-free nasal vaccine shows promise for COVID-19

AUG 8, 2022
Seres Therapeutics Announces Confirmatory Results From Ser-109 Ecospor Iv Open-Label Study In Recurrent C. Difficile Infection
Infectious Disease & AMR

Seres Therapeutics Announces Confirmatory Results From Ser-109 Ecospor Iv Open-Label Study In Recurrent C. Difficile Infection

JUN 8, 2022
Pherecydes Pharma Obtains AAC Early Access Program Approval From the ANSM for its anti-Staphylococcus aureus Phages
Infectious Disease & AMR

Pherecydes Pharma Obtains AAC Early Access Program Approval From the ANSM for its anti-Staphylococcus aureus Phages

JUN 6, 2022
Phage therapy: A model to predict its efficacy against pathogenic bacteria
Infectious Disease & AMR

Phage therapy: A model to predict its efficacy against pathogenic bacteria

MAY 23, 2022